PROCEPT BioRobotics (PRCT) Competitors $59.34 -0.73 (-1.21%) As of 12:37 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRCT vs. SOLV, PEN, STVN, GKOS, BLCO, IRTC, SLNO, TMDX, INSP, and NVSTShould you be buying PROCEPT BioRobotics stock or one of its competitors? The main competitors of PROCEPT BioRobotics include Solventum (SOLV), Penumbra (PEN), Stevanato Group (STVN), Glaukos (GKOS), Bausch + Lomb (BLCO), iRhythm Technologies (IRTC), Soleno Therapeutics (SLNO), TransMedics Group (TMDX), Inspire Medical Systems (INSP), and Envista (NVST). These companies are all part of the "medical equipment" industry. PROCEPT BioRobotics vs. Its Competitors Solventum Penumbra Stevanato Group Glaukos Bausch + Lomb iRhythm Technologies Soleno Therapeutics TransMedics Group Inspire Medical Systems Envista Solventum (NYSE:SOLV) and PROCEPT BioRobotics (NASDAQ:PRCT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation. Is SOLV or PRCT more profitable? Solventum has a net margin of 4.55% compared to PROCEPT BioRobotics' net margin of -36.20%. Solventum's return on equity of 31.01% beat PROCEPT BioRobotics' return on equity.Company Net Margins Return on Equity Return on Assets Solventum4.55% 31.01% 6.53% PROCEPT BioRobotics -36.20%-28.09%-20.02% Does the media favor SOLV or PRCT? In the previous week, Solventum had 1 more articles in the media than PROCEPT BioRobotics. MarketBeat recorded 12 mentions for Solventum and 11 mentions for PROCEPT BioRobotics. Solventum's average media sentiment score of 1.05 beat PROCEPT BioRobotics' score of 1.01 indicating that Solventum is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solventum 8 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PROCEPT BioRobotics 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation and earnings, SOLV or PRCT? Solventum has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSolventum$8.25B1.56$478M$2.1634.42PROCEPT BioRobotics$224.50M14.62-$91.41M-$1.70-34.90 Which has more risk and volatility, SOLV or PRCT? Solventum has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500. Comparatively, PROCEPT BioRobotics has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Do insiders and institutionals believe in SOLV or PRCT? 89.5% of PROCEPT BioRobotics shares are held by institutional investors. 0.1% of Solventum shares are held by insiders. Comparatively, 6.6% of PROCEPT BioRobotics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts rate SOLV or PRCT? Solventum presently has a consensus target price of $84.38, indicating a potential upside of 13.50%. PROCEPT BioRobotics has a consensus target price of $84.13, indicating a potential upside of 41.78%. Given PROCEPT BioRobotics' stronger consensus rating and higher possible upside, analysts clearly believe PROCEPT BioRobotics is more favorable than Solventum.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Solventum 1 Sell rating(s) 6 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.27PROCEPT BioRobotics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 SummarySolventum beats PROCEPT BioRobotics on 9 of the 16 factors compared between the two stocks. Get PROCEPT BioRobotics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRCT vs. The Competition Export to ExcelMetricPROCEPT BioRoboticsMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.29B$6.89B$5.68B$9.50BDividend YieldN/A1.30%4.05%3.99%P/E Ratio-34.9925.4627.9520.00Price / Sales14.6262.47397.1083.19Price / CashN/A20.2736.1958.45Price / Book7.704.768.665.83Net Income-$91.41M$176.14M$3.24B$258.39M7 Day Performance0.69%2.07%3.33%2.30%1 Month Performance0.69%4.04%10.84%12.42%1 Year Performance-12.03%7.28%35.32%21.16% PROCEPT BioRobotics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRCTPROCEPT BioRobotics2.7855 of 5 stars$59.34-1.2%$84.13+41.8%-13.5%$3.29B$224.50M-34.99430Positive NewsSOLVSolventum0.9719 of 5 stars$74.08+0.4%$81.50+10.0%+31.4%$12.82B$8.25B34.3022,000Positive NewsPENPenumbra4.613 of 5 stars$238.82+0.4%$305.07+27.7%+24.2%$9.25B$1.24B225.314,500Positive NewsUpcoming EarningsSTVNStevanato Group1.4013 of 5 stars€25.55+1.3%N/A+18.1%€7.74B€1.12B50.105,521Gap UpGKOSGlaukos4.4749 of 5 stars$104.43+0.6%$134.67+29.0%-23.4%$5.97B$404.52M-44.06780Positive NewsUpcoming EarningsBLCOBausch + Lomb2.1916 of 5 stars$13.67-1.5%$15.45+13.1%-16.3%$4.83B$4.83B-13.2713,500News CoverageUpcoming EarningsIRTCiRhythm Technologies1.2872 of 5 stars$138.91+2.2%$138.60-0.2%+34.4%$4.43B$591.84M-44.242,000Positive NewsUpcoming EarningsSLNOSoleno Therapeutics3.8025 of 5 stars$82.76+1.5%$108.70+31.3%+80.7%$4.17BN/A-17.9130Positive NewsTMDXTransMedics Group2.3666 of 5 stars$116.88+3.9%$127.33+8.9%-29.2%$3.95B$441.54M85.94210Positive NewsUpcoming EarningsINSPInspire Medical Systems4.9082 of 5 stars$130.17-0.1%$211.91+62.8%-5.3%$3.84B$802.80M59.981,246Positive NewsAnalyst ForecastNVSTEnvista3.5309 of 5 stars$20.05-0.8%$20.23+0.9%+27.8%$3.40B$2.51B-3.0712,300Upcoming Earnings Related Companies and Tools Related Companies SOLV Competitors PEN Competitors STVN Competitors GKOS Competitors BLCO Competitors IRTC Competitors SLNO Competitors TMDX Competitors INSP Competitors NVST Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRCT) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PROCEPT BioRobotics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share PROCEPT BioRobotics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRCT Stock Alerts